Who Paid My Doc
Sharad Patel
Critical Care Medicine Camden, NJ Medical Doctor
NPI 1093943631 CMS profile 821494
1 Cooper Plz, Camden, NJ 08103
General payments
$2,187
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Sharad Patel of Camden, NJ is reported in the CMS Open Payments database as having received $2,187 across 16 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 76th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $73 | 3 | |
| 2022 | General | $125 | 1 | |
| 2021 | General | $125 | 1 | |
| 2020 | General | $1,819 | 10 | |
| 2019 | General | $45 | 1 |
Beside peers
- Sharad Patel
- Critical Care Medicine median
- Middle half of Critical Care Medicine
- National median
In program year 2025, general payments to Sharad Patel were reported at $0. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.
Show as a table
| Year | Sharad Patel | Critical Care Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $45 | $149 | $51–$535 | $163 |
| 2020 | $1,819 | $110 | $30–$325 | $114 |
| 2021 | $125 | $125 | $34–$403 | $132 |
| 2022 | $125 | $157 | $49–$582 | $149 |
| 2023 | $73 | $162 | $56–$621 | $160 |
| 2024 | $0 | $168 | $53–$634 | $164 |
| 2025 | $0 | $189 | $59–$844 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 17 billing codesPaid by Medicare
$50,600
Medicare patients
282
Services billed
614
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 63% | |
| Ischemic heart disease | 62% | |
| Heart failure | 59% | |
| Chronic kidney disease | 59% | |
| Atrial fibrillation | 51% | |
| Arthritis | 48% | |
| COPD | 45% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
16 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Critical Care Medicine in New Jersey
Fariborz Rezai
Critical Care Medicine · Livingston, NJ
Eric Teller
Critical Care Medicine · Hackensack, NJ
R Phillip Dellinger
Critical Care Medicine · Camden, NJ
Raghad Said
Critical Care Medicine · Hackensack, NJ
Neha Vagadia
Critical Care Medicine · Marlton, NJ
Mark Ramzy
Critical Care Medicine · West Orange, NJ
Related records
Critical Care Medicine in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Critical Care Medicine
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.